Testing the Addition of a New Anti-cancer Drug, Radium-223 Dichloride, to the Usual Treatment (Cabozantinib) for Advanced Renal Cell Cancer That Has Spread to the Bone, RadiCaL Study
ACTIVE_NOT_RECRUITING
Status
Conditions
- Advanced Renal Cell Carcinoma
- Chromophobe Renal Cell Carcinoma
- Clear Cell Renal Cell Carcinoma
- Collecting Duct Carcinoma
- Kidney Medullary Carcinoma
- Metastatic Malignant Neoplasm in the Bone
- Papillary Renal Cell Carcinoma
- Stage IV Renal Cell Cancer AJCC v8
- Unclassified Renal Cell Carcinoma
Interventions
- PROCEDURE: Biospecimen Collection
- PROCEDURE: Bone Scan
- DRUG: Cabozantinib S-malate
- PROCEDURE: Computed Tomography
- PROCEDURE: Magnetic Resonance Imaging
- PROCEDURE: Positron Emission Tomography
- OTHER: Questionnaire Administration
- RADIATION: Radium Ra 223 Dichloride
Sponsor
National Cancer Institute (NCI)